Navigation Links
Masimo Reports Second Quarter 2011 Financial Results

IRVINE, Calif., Aug. 9, 2011 /PRNewswire/ --

Q2 2011 Highlights (compared to Q2 2010):

  • Total revenue, including royalties, rose 9% to $109.6 million
  • Product revenue rose 17% to $102.6 million
  • Masimo SET® and Masimo rainbow® SET unit shipments rose 2% to 37,300
  • Masimo rainbow revenue rose 26% to $9.1 million
  • GAAP EPS was $0.28 versus $0.24 in the prior period, which included $0.01 in one-time expenses.  Excluding the prior period one-time items, GAAP EPS rose 12% from an adjusted $0.25 in Q2 2010  

  • Masimo (NASDAQ: MASI) today announced its financial results for the second quarter ended July 2, 2011.

    Masimo’s total revenue, including royalties, for the second quarter rose 9% to $109.6 million, compared to $100.1 million for the second quarter of 2010.  Masimo’s second quarter product revenue rose 17% to $102.6 million, compared to $88.0 million for the second quarter of 2010.  Revenue from Masimo rainbow products rose 26% to $9.1 million in the second quarter, compared to $7.2 million for the second quarter of 2010.  

    Net income for the second quarter was $17.0 million, or $0.28 per diluted share, compared to reported net income of $14.3 million, or $0.24 per diluted share, in the second quarter of 2010, which included $0.01 per diluted share in one-time marketing-related expenses.  Excluding these one-time expenses, diluted earnings per share rose 12% in the second quarter of 2011 from the year-ago period.

    During the second quarter, the company shipped approximately 37,300 Masimo SET pulse oximetry and Masimo rainbow SET Pulse CO-Oximetry units, excluding handheld units, up 2% compared to approximately 36,700 in the same prior year period.  Masimo estimates its worldwide installed base as of July 2, 2011 to be 922,000 units, up 17% from 789,000 units as of July 3, 2010.As of July 2, 2011, cash and cash equivalents was $125.7 million, compared to $88.3 million as of January 1, 2011.Conference Call Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results.  The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers.  The reservation code for both dial-in numbers is 78780959.  After the live webcast, the call will be available on Masimo's website through September 9, 2011. In addition, a telephonic replay of the call will be available through August 16, 2011.  The replay dial-in numbers are (800) 642-1687 for domestic callers and +1 (706) 645-9291 for international callers. Please use reservation code 78780959.

    About Masimo Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care — helping solve "unsolvable" problems.  In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events.  More than 100 independent and objective studies demonstrate Masimo SET provides the most reliable SpO2 and pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion.  In 2005, Masimo introduced rainbow® SET Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI).  In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events.  In 2009, Masimo introduced rainbow Acoustic Monitoring™, the first-ever noninvasive and continuous monitoring of acoustic respiration rate (RRa™).  Masimo’s rainbow SET technology platform offers a breakthrough in patient safety by helping clinicians detect life-threatening conditions and helping guide treatment options.  In 2010, Masimo acquired SEDLine®, a pioneer in the development of innovative brain function monitoring technology and devices.  Masimo SET and Masimo rainbow SET technologies can also be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world.  Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care ... by Taking Noninvasive Monitoring to New Sites and Applications®."  Additional information about Masimo and its products may be found at

    Forward-Looking Statements All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about: our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies; and global demand for our technologies.  These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements.  These risks include, but are not limited to, those related to: our dependence on Masimo SET and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors' assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the impact of the decline in the worldwide credit markets on us and our customers; the amount and type of equity awards that we may grant to employees and service providers in the future; and other factors discussed in the "Risk Factors" section of our most recent periodic reports filed with the Securities and Exchange Commission ("SEC"), which you may obtain for free on the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct.  You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise.  We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Investor Contact: Sheree AronsonMedia Contact: Dana BanksVice President, Investor Relations, Masimo CorporationDirector, Corporate Communications, Masimo Corporation (949) 297-7043 (949) 297-7348 saronson@masimo.comdbanks@masimo.comMasimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57, Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, and SEDLine are trademarks or registered trademarks of Masimo Corporation.

    MASIMO CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited, in thousands) July 2,January 1,20112011ASSETSCurrent assetsCash and cash equivalents



    88,305Accounts receivable, net of allowance for doubtful accounts 52,03649,694Royalties receivable7,25212,000Inventories44,95445,028Prepaid expenses9,9767,887Deferred tax assets12,56112,555Other current assets1,8062,136Total current assets254,279217,605Deferred cost of goods sold52,38047,184Property and equipment, net15,13215,951Intangible assets, net10,47210,497Deferred tax assets12,57912,560Other assets6,9006,438Total assets



    310,235LIABILITIES AND EQUITYCurrent liabilitiesAccounts payable



    22,150Accrued compensation15,08721,074Accrued liabilities10,4269,832Income taxes payable1,327722Deferred revenue15,26816,369Current portion of capital lease obligations4750Total current liabilities62,28270,197Deferred revenue1,2621,554Capital lease obligations, less current portion99122Other liabilities9,0038,323Total liabilities72,64680,196EquityMasimo Corporation stockholders’ equity:Common stock6059Treasury stock(1,209)(1,209)Additional paid-in capital235,992222,206Accumulated other comprehensive income1,092925Retained earnings40,7155,664Total Masimo Corporation stockholders’ equity276,650227,645Noncontrolling interest2,4462,394Total equity279,096230,039Total liabilities and equity



    310,235MASIMO CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in thousands, except per share amounts) Three Months EndedSix Months EndedJuly 2,July 3,July 2,July 3,2011201020112010Revenue:Product$




    173,824Royalty7,01012,12218,47525,021Total revenue109,565100,080222,607198,845Cost of goods sold34,31429,77570,52459,003Gross profit75,25170,305152,083139,842Operating expenses:Selling, general and administrative43,67341,00485,14190,315Research and development9,4469,05119,42118,461Antitrust litigation proceeds—(760)—(30,728)Total operating expenses53,11949,295104,56278,048Operating income22,13221,01047,52161,794Non-operating income (expense)528309722(38)Income before provision for income taxes22,66021,31948,24361,756Provision for income taxes5,7517,40313,18021,676Net income including noncontrolling interests16,90913,91635,06340,080Net (income) loss attributable to the noncontrolling interests129371(12)917Net income attributable to Masimo Corporation$




    40,997Net income per share attributable to Masimo Corporation stockholders:Basic$








    0.68Weighted average shares used in per share calculations:Basic59,84258,79859,72058,532Diluted61,23260,51061,09660,496Cash dividend declared per share$




    2.00The following table presents details of the share-based compensation expense that is included in each functional line item in the condensed consolidated statements of income above (in thousands): Three Months EndedSix Months EndedJuly 2,July 3,July 2,July 3,2011201020112010Cost of goods sold$




    211Selling, general and administrative3,1322,6595,6474,736Research and development8747231,6461,371Total$




    6,318 MASIMO CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited, in thousands) Six Months EndedJuly 2,July 3,20112010Cash flows from operating activities:Net income including noncontrolling interests



    40,080Adjustments to reconcile net income including noncontrolling interests to net cash provided by operating activities:Depreciation and amortization3,8403,151Share-based compensation7,5746,318Provision for doubtful accounts92154Provision for obsolete inventory850359Provision for warranty costs1,3341,150Provision for deferred income taxes—133Income tax benefit from exercise of stock options granted prior to January 1, 20061,0581,631Excess tax benefit from share-based payment arrangements(89)(537)Changes in operating assets and liabilities:Increase in accounts receivable(2,433)(10,338)Decrease in royalties receivable4,748—Increase in inventories(776)(5,910)Increase in deferred cost of goods sold(5,135)(4,499)(Increase) decrease in prepaid expenses(2,043)1,243Increase in other assets(101)(1,963)Increase (decrease) in accounts payable(2,045)5,084Decrease in accrued compensation(6,257)(1,752)Decrease in accrued liabilities(831)(1,291)Increase in income taxes payable6761,073Increase (decrease) in deferred revenue(1,394)2,703Increase in other liabilities6541,064Net cash provided by operating activities34,78537,853Cash flows from investing activities:Purchase of short-term investments—(75,986)Proceeds from sale and maturities of short-term investments—132,975Purchases of property and equipment(2,123)(3,930)Increase in intangible assets(848)(911)Net cash provided by (used in) investing activities(2,971)52,148Cash flows from financing activities:Repayments of capital lease obligations(27)(28)Proceeds from issuance of common stock5,1275,662Excess tax benefit from share-based payment arrangements89537Dividends paid—(117,506)Net cash provided by (used in) financing activities5,189(111,335)Effect of foreign currency exchange rates on cash386251Net increase (decrease) in cash and cash equivalents37,389(21,083)Cash and cash equivalents at beginning of period88,305132,054Cash and cash equivalents at end of period




    SOURCE Masimo Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Masimo Announces Adoption of Stock Repurchase Program
    2. Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
    3. Masimo to Report Second Quarter 2011 Financial Results after Market Close on August 9, 2011
    4. Masimo and Dartmouth-Hitchcock Medical Center, First Cross-Industry Collaborative Honored With the Institute for Technology and Healthcare Clinical Application Award
    5. Masimo Announces Rainbow Agreement with Philips
    6. Masimo Pronto-7 Wins GOLD in the 2011 Medical Design Excellence Award Competition—the Premier Awards Program for the Medical Technology Community
    7. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
    8. Masimo to Present at Goldman Sachs 32nd Annual Global Healthcare Conference
    9. Masimo Reports First Quarter 2011 Financial Results
    10. Masimo Launches New Reusable SpCO® Sensor with Improved Accuracy and Reliability in Low Oxygen Saturation and Elevated Methemoglobin States
    11. New Published Study Finds Masimo Noninvasive SpCO Effective for Screening Emergency Department Patients for Carbon Monoxide Poisoning
    Post Your Comments:
    (Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
    (Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
    (Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
    (Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
    (Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
    (Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
    (Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
    Breaking Medicine News(10 mins):